ALK fusion-positive adenocarcinoma showed a similar pattern (49.1 vs. 40.3 months; HR 0.69, 95% CI: 0.49 –0.97, p = 0.034) (Figure 2f). This evidence concerns the gene ALK and adenocarcinoma.